P2, N=50, Recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Jan 2029 | Trial primary completion date: Nov 2025 --> Jul 2027

Despite poor overall outcomes, incremental progress across targeted, immune, and delivery-based approaches supports a patient centered strategy emphasizing clinical-trial enrollment, molecular profiling and symptom focused care.

P4, N=75, Recruiting, Hebei Medical University Fourth Hospital | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Oct 2024 --> Oct 2026

P=N/A, N=10, Not yet recruiting, University of Cincinnati

P2, N=15, Recruiting, IRCCS Azienda Ospedaliero-Universitaria di Bologna

P2, N=800, Not yet recruiting, Innovent Biologics Technology Limited (Shanghai R&D Center)

P3, N=18, Terminated, Fondation Ophtalmologique Adolphe de Rothschild | N=30 --> 18 | Suspended --> Terminated; Study futility based on the interim analysis

She showed a sustained clinical response to fourth-line treatment with the PARP inhibitor olaparib, which lasted 15 months and led to improved performance status. Subsequent progression led to combination therapy with atezolizumab and bevacizumab, maintaining stable disease for eight months. Molecularly guided treatment resulted in an overall survival of 25 months.

P=N/A, N=300, Completed, Sun Yat-sen University

P1, N=8, Completed, Precision Biotech Taiwan Corp.

P2, N=50, Not yet recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Dec 2028 --> Jan 2030 | Trial primary completion date: May 2028 --> Jan 2030

These findings provide both a valuable guide for determining treatment strategies in routine clinical practice and a foundation for future immunotherapy development for the treatment of advanced hepatocellular carcinoma. The study protocol was registered on the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) (UMIN000047701).